A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Trial Identifier: 3475-048
Sponsor: MSD
Start Date: March 2015
Primary Completion Date: February 2019
Study Completion Date: July 2023
Condition: Head and Neck Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Results Plain Language Summary – EMEA Greek
Results Plain Language Summary - LA Portuguese
Results Plain Language Summary – EMEA Norwegian
Results Plain Language Summary – EMEA Xhosa
Results Plain Language Summary – EMEA Estonian
Results Plain Language Summary – EMEA Swedish
Results Plain Language Summary – EMEA Zulu
Results Plain Language Summary – EMEA Swedish
Results Plain Language Summary – EMEA Dutch
Results Plain Language Summary – EMEA Czech
Results Plain Language Summary – EMEA Afrikaans
Results Plain Language Summary – EMEA Russian
Results Plain Language Summary – EMEA German
Results Plain Language Summary - LA Spanish
Results Plain Language Summary – EMEA Setswana
Results Plain Language Summary – EMEA Hungarian
Results Plain Language Summary – NA French Canadian
Results Plain Language Summary – EMEA Finnish
Results Plain Language Summary – EMEA Spanish
Results Plain Language Summary – EMEA Latvian
Results Plain Language Summary – EMEA Sepedi
Results Plain Language Summary – EMEA Turkish
Results Plain Language Summary – EMEA Danish
Results Plain Language Summary – English
Results Plain Language Summary – EMEA Polish
Results Plain Language Summary – EMEA Sesotho
Results Plain Language Summary – EMEA Italian
Results Plain Language Summary – EMEA German

Trial Locations

No locations posted.